Protalix BioTherapeutics (PLX) Enterprise Value (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Enterprise Value of -$10.8 million for Q1 2026, up 68.93% year-over-year from -$6.4 million in Q1 2025, and up 33.76% quarter-over-quarter from -$16.3 million in Q4 2025.
Protalix BioTherapeutics (PLX) Enterprise Value (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$10.8 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 68.93% year-over-year to -$10.8 million; the TTM figure through Mar 2026 stood at -$10.8 million (up 68.93% YoY), while the FY2025 annual figure was -$16.3 million, up 53.22% from the prior year.
- Enterprise Value for Q1 2026 stood at -$10.8 million, up from -$16.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$10.8 million in Q1 2026, with the low at -$48.5 million in Q1 2024.
- The 5-year median for Enterprise Value is -$33.0 million (2023), against an average of -$32.4 million.
- The sharpest annual moves came in 2023 and 2026: Enterprise Value sank 100.9% in 2023, then soared 68.93% in 2026.
- Protalix BioTherapeutics' Enterprise Value stood at -$22.2 million in 2022, then plunged by 100.9% to -$44.6 million in 2023, then grew by 21.84% to -$34.8 million in 2024, then surged by 53.22% to -$16.3 million in 2025, then soared by 33.76% to -$10.8 million in 2026.
- Business Quant data shows PLX's Enterprise Value at -$10.8 million in Q1 2026, -$16.3 million in Q4 2025, and -$29.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -40.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.66 Mn |
| Mar 31, 2026 | -10.79 Mn |
| Dec 31, 2025 | -16.30 Mn |
| Sep 30, 2025 | -29.37 Mn |
| Jun 30, 2025 | -33.40 Mn |
| Mar 31, 2025 | -34.74 Mn |
| Dec 31, 2024 | -34.83 Mn |
| Sep 30, 2024 | -27.41 Mn |
| Jun 30, 2024 | -45.03 Mn |
| Mar 31, 2024 | -48.49 Mn |
| Dec 31, 2023 | -44.56 Mn |
| Sep 30, 2023 | -40.98 Mn |
| Jun 30, 2023 | -48.18 Mn |
| Mar 31, 2023 | -33.04 Mn |
| Dec 31, 2022 | -22.18 Mn |
| Sep 30, 2022 | -20.81 Mn |
| Jun 30, 2022 | -28.57 Mn |
| Mar 31, 2022 | -32.92 Mn |
| Dec 31, 2021 | -38.99 Mn |
| Sep 30, 2021 | -48.66 Mn |